Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAmeriHealth Medicare PPO Formulary Coverage Update…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAmeriHealthPolicy FID 00026201

    AmeriHealth Medicare PPO 2026 Formulary (Drug List)

    Customize your policy alerts

    Sign up for AmeriHealth Policy FID 00026201 alerts

    Get alerted when Policy FID 00026201 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document describes the AmeriHealth Medicare PPO 2026 formulary, including coverage rules (prior authorization, step therapy, quantity limits), member exception and transition supply rights, and where to find drug coverage information for plan members and their prescribers/pharmacies.

    Policy Summary
    PayerAmeriHealth
    PolicyAmeriHealth Medicare PPO 2026 Formulary (Drug List)
    Policy CodePolicy FID 00026201
    Change TypeNo material changes
    Effective Date1/20/2026
    Next Review DateN/A
    Key ActionObtain prior authorization when a drug line is flagged 'PA' to avoid coverage denial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1/20/2026document current as of
    monthlyformulary updates posted online
    72h / 24hdecision timeframe for exception requests
    30-daytransition supply coverage
    30 daysadvance notice for midyear changes

    Coverage Criteria & Formulary Rules

    inv-01: General Coverage Conditions

    Covered when ALL of the following are met:

    General coverage conditions: Drug is listed on the AmeriHealth Medicare PPO formulary, is medically necessary, the prescription is filled at an AmeriHealth Medicare PPO network pharmacy, and other plan rules are followed.

    Based on formulary definition and coverage statement.

    inv-02: Formulary Exception Timelines

    Decision timing for exception requests:

    Exception decision timeline: The plan must make a decision on a formulary or coverage restriction exception within 72 hours of receiving the prescriber's supporting statement; expedited requests must be decided within 24 hours.72 hours / 24 hours expedited

    Prescriber must provide supporting clinical statement with the request.

    Policy Summary
    PayerAmeriHealth
    PolicyAmeriHealth Medicare PPO 2026 Formulary (Drug List)
    Policy CodePolicy FID 00026201
    Change TypeNo material changes
    Effective Date1/20/2026
    Next Review DateN/A
    Key ActionObtain prior authorization when a drug line is flagged 'PA' to avoid coverage denial.
    SourceLink
    On This Page
    Coverage Criteria & Formulary RulesCoding and Selected CodesProvider Actions, Authorization & DocumentationBackground & ScopeKey Definitions & SymbolsStep Therapy Rules & FlagsQuantity Limits by Drug / StrengthPolicy Revision History

    inv-03: Transition and Emergency Supply

    Temporary coverage during member transitions or new membership:

    Transition supplies: For each drug not on the formulary or subject to a restriction, the plan will cover a temporary 30-day supply while member and prescriber pursue coverage or an exception.30 days (31 days for long-term care residents)

    If coverage is not approved after the first 30-day supply, the plan will not pay subsequently; LTC residents may receive a 31-day emergency supply.

    inv-04: Formulary listing (coverage with criteria flags)

    Formulary coverage with utilization management annotations:

    Formulary entries: Each drug/strength line displays a Tier Requirements/Limits value and may include utilization management flags such as PA (prior authorization), QL (quantity limit), ST (step therapy), NDS, or NF (non‑formulary). Coverage and additional requirements are determined by those flags shown for the specific product/strength.

    Excerpt shows presence of PA/QL/NF per line but does not include full clinical criteria or step sequences.

    inv-05: Tier assignments and formulary flags

    Formulary coverage and restrictions by product/strength:

    Tier or NF assignment: Each listed drug entry includes a 'Tier Requirements/Limits' value (numeric tier or 'NF' for non‑formulary) which determines formulary placement, member cost‑share, and whether an exception is required for coverage.

    Refer to symbol definitions (see page 6) for full meaning of NF, PA, QL, ST, NDS.

    inv-06: Prior authorization and quantity limits

    Utilization management requirements where specified:

    PA and QL flags: Some formulations are flagged with prior authorization (PA) and/or quantity limits (QL) including explicit maximums per time period. Examples in the excerpt include: CORLANOR oral solution (PA; QL 450 mL/30 days), ENTRESTO capsule sprinkle (QL 240 EA/30 days), sildenafil 20 mg (PA; QL 360 EA/30 days), tadalafil and VERQUVO (PA; QL 30 EA/30 days).

    Providers must follow payer PA process and respect listed QL when adjudicating claims; exceeding QL may trigger PA or denial.

    In the formulary table the notation Non-Formulary (NF) indicates that the drug is not covered under the AmeriHealth Medicare PPO plan. Members and prescribers may request a Formulary Exception if a medically necessary reason exists for coverage of an NF drug; the exception process and required supporting statement are described elsewhere in the formulary.

    The extracted formulary lines in this segment do not include discrete medical‑necessity criteria or indication‑specific exclusion language. Entries are limited to the drug name and the Tier Requirements/Limits column showing tier placement and annotations such as PA (prior authorization) and QL (quantity limit); clinical PA criteria are not provided in these chunks.

    Multiple individual formulary rows in this extract are annotated with NF in the Tier Requirements/Limits column. Each line marked NF denotes that particular product/strength is classified as non‑formulary (not included on the plan’s drug list).

    A drug designated Non‑Formulary (NF) is not covered by the plan unless the member obtains an approved formulary exception. Failure to secure an approved exception means the plan may not pay for the NF drug.

    Coding and Selected Codes

    Selected therapy packs with QLmixed
    PAXLOVID (150/100) ORAL TABLET THERAPY PACKTier Requirements/Limits = QL (20 EA per 5 days)
    PAXLOVID (300/100 & 150/100) ORAL TABLET THERAPY PACKTier Requirements/Limits = QL (11 EA per 5 days)
    PAXLOVID (300/100) ORAL TABLET THERAPY PACKTier Requirements/Limits = QL (30 EA per 5 days)
    EPCLUSA entries with PA/QLmixed
    EPCLUSA ORAL PACKET 150-37.5 MGTier Requirements/Limits = PA; QL (84 EA per 365 days)
    EPCLUSA ORAL PACKET 200-50 MGTier Requirements/Limits = PA; QL (168 EA per 365 days)
    EPCLUSA ORAL TABLET 200-50 MGTier Requirements/Limits = PA; QL (168 EA per 365 days)
    Formulary flags / quantity limitsmixed
    QL (240 EA per 30 days)Quantity limit for ENTRESTO oral capsule sprinkle
    QL (60 EA per 30 days)Quantity limit shown for sacubitril-valsartan and tadalafil (as listed)
    QL (30 EA per 30 days)Quantity limit shown for VERQUVO and some valsartan 320 mg
    PA; QL (360 EA per 30 days)PA and QL shown for sildenafil 20 mg
    PA; QL (450 ML per 30 days)PA and QL shown for CORLANOR oral solution
    PA; QL (60 EA per 30 days)PA and QL shown for tadalafil (PA; QL (60 EA per 30 days))
    Quantity limit example — single example
    Example quantity limitQL = 84 EA per 28 days (IMIPAVIDO / IMPAVIDO oral capsule)
    ContextShown in formulary lines as a product-specific quantity limit (example: IMPAVIDO / IMIPAVIDO listing).
    ImplicationClaims exceeding this quantity may require prior authorization or be denied if not supported per plan rules.
    Quantity Limits examples — assorted
    EPCLUSA packets/tabletsPA; QL = 84–168 EA per 365 days (varies by strength/formulation)
    Emtricitabine-tenofovir and similar ARVsQL = 30 EA per 30 days for many single-tablet regimens
    PAXLOVID therapy packsQL examples: 11 EA per 5 days; 30 EA per 5 days (varies by pack)
    Quantity limit examples — varenicline, inhalers, XARELTO
    Varenicline tartrateQL = 504 EA per 365 days (starter and tablet listings)
    Fluticasone-salmeterol (powder inhalation)QL = 60 EA per 30 days
    XARELTO oral suspension (reconstituted)QL = 600 ML per 30 days
    Quantity limits (examples) — biologic/injectable QLs and tablet counts
    Injectable biologics (pegfilgrastim biosimilars)QL = 2.4 mL per 28 days (examples: NEULASTA, UDENYCA, others)
    PROMACTA tablets (by strength)QLs = 360 EA/30 days (12.5 mg), 180 EA/30 days (25 mg), 90 EA/30 days (50 mg), 60 EA/30 days (75 mg)
    VENCLEXTA starting packQL = 84 EA per 365 days
    Quantity limit examples — EA/30 days, mL volumes
    PROAIR RESPICLICKQL = 2 EA per 30 days
    XARELTO oral suspension (reconstituted)QL = 600 ML per 30 days
    MIEBO ophthalmic solutionQL = 12 ML per 30 days

    Provider Actions, Authorization & Documentation

    Prior Authorization

    Prior Authorization Required

    Prior Authorization (PA) is required for many drugs listed in the formulary. When a drug row shows the "PA" symbol in the Requirements/Limits column, the prescriber or member must obtain approval from AmeriHealth before the prescription is filled. Failure to obtain required PA may result in the plan denying coverage for the drug.

    • Check the Requirements/Limits column in the formulary for "PA" before prescribing or dispensing.
    • Obtain prior authorization before filling PA‑flagged products to avoid claim denial.
    Prior Authorization

    Quantity Limits May Trigger Authorization

    Quantity limits (QL) shown in formulary rows may restrict the amount covered and can trigger the need for authorization or an exception if a higher quantity is clinically necessary. QLs must be documented on claims and on authorization requests.

    • Examples: QL (84 EA per 28 days), QL (168 EA per 365 days), QL (10 ML per 30 days).
    • Document the requested quantity and clinical rationale when requesting PA or an exception for amounts above the QL.
    Prior Authorization

    PA for Specialty and Select Formulations

    Many specialty, oncology, and select formulations are PA‑flagged (showing "PA" and often a QL). Providers should anticipate PA requirements for specialty oral agents, injectables, transdermal patches, and certain solutions.

    • Specialty oncology examples: PIQRAY, ROZLYTREK, RUBRACA, RYDAPT, SCEMBLIX (PA; QL noted on some strengths).
    • Specialty examples across the formulary include many oral targeted therapies and high-cost agents listed with PA.
    Prior Authorization

    Prior Authorization Applies to Specific Products

    Some common products and classes have specific PA or QL rules (for example, select erythropoiesis-stimulating agents, sodium oxybate, EMSAM, NUEDEXTA, and VMAT2 inhibitors). Review formulary rows for PA and QL flags before ordering or dispensing.

    • Examples: DOPTELET and PROCRIT list PA or QL requirements; sodium oxybate and EMSAM show PA; AUSTEDO/AUSTEDO XR show PA; XDEMVY listed as PA; QL (10 ML per 30 days).
    • If a product is PA‑flagged, submit an authorization request with clinical documentation prior to dispensing.
    Prior Authorization

    Opioid Supply, PA and Quantity Limits

    Selected opioids and long‑acting opioid formulations have Non‑Extended Day Supply (NDS), Quantity Limits and/or PA. Providers must follow opioid supply limits and obtain PA where required.

    • Fentanyl transdermal patches: some strengths list PA; NDS; QL (15 EA per 30 days).
    • Morphine ER: certain strengths list PA; NDS; QL (90 EA per 30 days).
    • All opioid fills are subject to the plan's NDS/30‑day retail limit and may have additional pharmacy or home‑delivery rules.
    Documentation Required

    Documentation Required for PA and Exception Requests

    When prior authorization or quantity limit documentation is required, prescribers should submit supporting clinical documentation and a medical statement explaining the need for the drug or an exception to the restriction. The plan generally issues decisions within 72 hours (or 24 hours for expedited requests) upon receipt of the prescriber's supporting statement.

    • Include diagnosis, prior therapies tried (for Step Therapy), clinical rationale for exceeding QL or for a non‑formulary drug, and relevant labs or notes.
    • Request expedited review if waiting could seriously harm the member; expedited decisions are rendered within 24 hours when approved.
    Billing Rule

    Follow Listed Tier Requirements / Limits

    Follow the formulary's Tier Requirements/Limits values when adjudicating coverage. Tier assignments indicate preferred versus non‑preferred products and may affect cost‑sharing and the need for PA, ST, or QL compliance.

    • Review Tier, PA, ST, QL, NDS, and NF flags in the Requirements/Limits column for each product.
    • Tiering/tier exceptions can be requested via the formulary exception process; prescriber must provide supporting medical reasons.
    Step Therapy

    Step Therapy: Requirements and Flags

    Step Therapy (ST) applies to select agents; when a product is marked 'ST' providers must document trials of required preferred agents before the plan will cover the requested drug. The formulary does not detail all step algorithms in this excerpt — consult the plan documents or website for full ST protocols.

    • Examples: SAVELLA, FANAPT, FETZIMA, SECUADO, SANCUSO have ST flags on some strengths/forms.
    • If ST applies, include documentation of inadequate response or intolerance to required step drugs when submitting an exception or PA request.
    Documentation Required

    Use Formulary Notation When Submitting Requests

    Use formulary notation (NF, PA, QL, ST, NDS) when submitting prior authorization, exception, or appeal requests. These notations determine which operational rules apply and which documentation is needed.

    • Consult page 6 (symbol definitions) for full meanings of NF, PA, QL, ST, NDS.
    • Reference the exact formulary row and notation (e.g., "EPCLUSA — PA; QL (84 EA per 365 days)") on the request to avoid processing delays.
    Note

    Formulary Symbol Guidance

    Formulary symbols and abbreviations are defined in the plan materials (see page 6). Confirm symbol meanings (PA, QL, ST, NDS, NF) before adjudicating claims or preparing authorization requests.

    • Page 6 contains the official key for formulary symbols — verify interpretation before submission.
    • When in doubt, contact AmeriHealth or refer to the online plan documents for clarification.

    Background & Scope

    This formulary groups drugs by therapeutic area and lists each product with a Tier Requirements/Limits value that indicates coverage status (numeric tier or NF) and any utilization management flags such as PA or QL. The table is intended to communicate formulary placement, required prior authorization, quantity limits, and whether a drug is non‑formulary; definitions and symbol meanings are referenced elsewhere in the formulary (see page 6).

    Key Definitions & Symbols

    Formulary / Drug List definition — definition and scope
    DefinitionFormulary (Drug List): a list of covered drugs selected by AmeriHealth Medicare PPO; coverage is conditioned on medical necessity, use of network pharmacies, and plan rules.
    ScopeIncludes brand and generic drugs, biologics and biosimilars; details tier, prior authorization, quantity limits, and step therapy where applicable.
    How to useCheck the Requirements/Limits column for PA, QL, ST, NF notations and consult Evidence of Coverage for substitution and coverage details.
    Biosimilar / Interchangeable Biosimilar — definition
    DefinitionBiosimilars: alternatives to original biological products; interchangeable biosimilars may be substituted for the original product at the pharmacy without a new prescription depending on state law.
    ImplicationMay lower cost and be listed on the formulary as substitutes for original biological products.
    ReferenceSee Evidence of Coverage, Chapter 5, Section 3.1 for discussion of drug types and substitution rules.
    NF — symbol reference (see page 6 for full definition)
    Symbol: NFNF = Non‑Formulary — drug is not covered under the plan; members may request a formulary exception.
    Location of full definitionFull symbol definitions are provided on page 6 of the formulary (referenced in the document).
    EffectNF status requires an exception request for coverage consideration.
    QL — symbol reference and example
    Symbol: QLQL = Quantity Limit — plan limits the amount covered for certain drugs (example shown: QL (84 EA per 28 days)).
    ApplicationSpecific QL values are listed next to drug/strength lines in the formulary table.
    ConsequenceExceeding QL may require prior authorization or result in claim denial without approval.
    NF — table notation example
    Example notationTable uses 'NF' to mark non‑formulary products; see page 6 for symbol meanings.
    ImplicationLines marked NF indicate the drug is not covered unless an exception is approved.
    ActionMembers or prescribers may request a formulary exception for NF drugs per plan procedures.
    QL — quantity limit definition example
    QL example in tableQuantity limits are shown as QL with amount/time (e.g., QL (84 EA per 28 days); QL (60 EA per 30 days)).
    Where listedQL entries appear in the Tier Requirements/Limits column next to specific drug/strength lines.
    Provider noteDocument QL values on claims/PA requests when applicable.
    PA — prior authorization definition
    DefinitionPrior Authorization (PA): approval that the plan requires before certain drugs will be covered; failure to obtain PA may result in non‑coverage.
    How it appliesPA is indicated in the formulary Requirements/Limits column for specific drugs or strengths.
    Provider actionSubmit an authorization request and supporting clinical documentation per AmeriHealth procedures when PA is shown.
    QL — quantity limit example (varenicline 504 EA/365 days)
    Varenicline tartrateQL = 504 EA per 365 days (CHANTIX / varenicline listings)
    NotesListed as QL in formulary lines for starter and regular tablet packs.
    ImplicationClaims exceeding this annual limit may require PA or exception.
    PA — prior authorization definition (alternate chunk)
    PA definition (alt)Prior Authorization — plan requires pre‑approval for certain drugs; if not obtained the plan may not cover the drug.
    ReferenceSee formulary Requirements/Limits column and Evidence of Coverage for PA procedures.
    RecommendationProviders should submit clinical rationale and supporting documentation with PA requests.
    NF — notation referenced (page 6)
    NF notation reference'NF' appears in the table to denote non‑formulary items; full meanings of symbols are available on page 6.
    ImplicationNF items are not covered under the plan unless an exception is approved.
    Provider actionRefer to page 6 for symbol definitions when interpreting formulary rows.
    NF — notation example
    Notation exampleThe formulary table uses symbols (e.g., NF) next to drug names; see page 6 for full definitions.
    UseSymbols indicate coverage status and any utilization management controls.
    ActionConsult the legend on page 6 when questions arise about listed flags.
    PA; QL — combined flags definition example
    Combined flags'PA; QL' indicates the product requires prior authorization and has a specified quantity limit (examples: CORLANOR oral solution PA; QL (450 ML per 30 days)).
    Provider implicationRequests should include documentation supporting both medical necessity and quantity justification.
    Check detailsRefer to the specific formulary line for the exact QL value and PA requirement per strength/formulation.
    NF — non‑formulary label example
    Non‑formulary labelExample: lines marked 'NF' (e.g., CAMBIA ORAL PACKET) indicate non‑formulary status in the table.
    EffectNF entries are not covered unless an exception is granted.
    Next stepMembers/prescribers may request a formulary exception per plan procedures.
    PA — prior authorization label example
    PA label exampleExample: carisoprodol 250 mg shows 'PA' in the Requirements/Limits column indicating prior authorization is required.
    ActionProvider must obtain PA prior to coverage for listed formulations.
    DocumentationSubmit clinical rationale supporting the need for the PA per AmeriHealth procedures.
    QL — quantity limit label example
    QL label exampleExamples include QL (60 EA per 30 days) for fluticasone‑salmeterol and QL (30 EA per 30 days) for some valsartan strengths.
    PlacementQL values appear in the Tier Requirements/Limits column next to product/strength lines.
    Provider noteAdhere to these limits or submit PA/exception when clinically justified.
    NDS — not drug specified flag explanation reference
    NDS explanationNDS = Not Drug Specified — an internal flag used in formulary lines (appears with certain opioid/controlled product listings).
    ImplicationNDS may indicate dispensing or claim handling specifics; check formulary line for details.
    ExampleSeen alongside PA and QL for some opioid and extended‑release products.
    NF — notation (alternate chunk)
    Alternate NF chunkSome immune globulin products and other lines are marked NF in the formulary (see immune globulin listings).
    MeaningNF denotes not covered on the formulary unless an exception is approved.
    ReferenceSee page 6 legend for symbol meanings.
    Symbols/Abbreviations — doc references symbols defined on another page
    Symbols/AbbreviationsThe formulary uses symbols (e.g., PA, QL, ST, NF, numeric tiers) and refers readers to page 6 for definitions.
    Where foundLegend and full definitions appear on page 6 of the formulary document.
    User actionConsult the legend when interpreting Tier Requirements/Limits entries.
    PA — prior authorization example (XDEMVY)
    PA example (XDEMVY)XDEMVY OPHTHALMIC SOLUTION = PA; QL (10 ML per 30 days)
    ImplicationRequires prior authorization and has a 10 mL/30‑day quantity limit per formulary line.
    Provider actionSubmit PA with supporting clinical documentation to request coverage.
    QL — quantity limit examples (mL/EA examples)
    mL and EA examplesExamples include QL (2.4 ML per 28 days) for some injectables and QL (8 EA per 28 days) or (24 EA per 28 days) for XPOVIO packs.
    Respiratory/inhaler examplesFluticasone‑salmeterol QL = 60 EA per 30 days; ADVAIR HFA QL = 12 GM per 30 days.
    Ophthalmic/other volumesRESTASIS QL = 60 ML per 30 days; XDEMVY QL = 10 ML per 30 days.
    ST — step therapy definition reference
    ST definitionST = Step Therapy — requires trying specified preferred drugs first before the plan will cover an alternative drug for the same condition.
    ApplicationSome formulary lines are marked 'ST' indicating step therapy edits apply (see specific product rows).
    Next stepsFollow the formulary or submit exception requests when step therapy requirements cannot be met clinically.

    Step Therapy Rules & Flags

    Step therapy overview
    Member must try specified preferred drug(s) first before the plan will cover an alternative drug for the same condition (step therapy).
    Step therapy absence note
    No explicit step therapy algorithm is detailed in these formulary chunks; entries show tiering and PA/QL annotations rather than step sequences.
    Step therapy not present in extract
    Step therapy details are not present in this extract; refer to the formulary legend (page 6) or the full formulary for step therapy rules.
    No explicit step therapy steps provided
    These entries identify Tier, PA, QL and NF status but do not provide explicit step‑therapy sequences or required prior medication trials in this excerpt.
    PA/QL flagged but no step sequences
    PA and QL flags are shown on many formulary lines; however, explicit step therapy steps or sequencing are not included in these chunks.
    No step‑therapy entries in excerpt
    No explicit step‑therapy entries appear in this excerpt; only tier, PA, and QL indicators are provided for listed products.
    Tier assignments vs step therapy
    Tier assignments (numeric tiers and 'NF') indicate preferred versus non‑preferred products, but explicit drug‑to‑drug step therapy failure rules are not present in these chunks.
    Tier numbers provided but no sequences
    Tier numbers are shown for products (e.g., tiers 2–5) but no explicit step therapy sequences or required prior trials are listed in these chunks.
    SAVELLA — ST indicated
    SAVELLA oral tablet entries include 'ST' indicating step therapy is required for some strengths (e.g., 100 mg shows ST; lower strengths show ST with QL).
    FANAPT and FETZIMA — ST
    FANAPT and FETZIMA are labeled 'ST' in the formulary, indicating step therapy edits apply prior to coverage for those products.
    SECUADO — ST
    SECUADO transdermal patch is listed with 'ST', indicating step therapy is required for that transdermal formulation.
    Tier influence on step/coverage
    Tier assignments shown in the extract may influence step therapy or coverage preference, but explicit step‑therapy logic is not contained in these chunks.
    SANCUSO — ST referenced
    SANCUSO transdermal patch listing references 'ST' alongside other controls (PA/QL), indicating step therapy may be required prior to coverage.

    Quantity Limits by Drug / Strength

    Glipizide ER 10 mg — QL 60
    Glipizide ER 10 mgQL = 60 per prescription (example in coverage restrictions text)
    ContextProvided in the document as an example of a product‑level quantity limit in addition to standard supply rules.
    ReferenceSee 'Are there any restrictions on my coverage?' section for example listing.
    IMIPAVIDO (oral capsule) — QL 84
    IMIPAVIDO (IMPAVIDO) oral capsuleQL = 84 EA per 28 days (listed in formulary lines)
    Tier/StatusListed with QL in the Antiprotozoals/antivirals section of the formulary.
    Provider noteAdhere to QL or submit PA/exception when clinically necessary.
    EPCLUSA oral packet/tablet — QL 84-168 EA per 365 days
    EPCLUSA (packets/tablets)PA; QL = 84–168 EA per 365 days depending on strength/formulation
    Formulary tierListed at tier 5 with PA and QL annotations in the formulary table.
    Provider actionPA required and QL enforced — include QL consideration in authorization/claims.
    PAXLOVID therapy packs — QL 11-30 EA per 5 days
    PAXLOVID therapy packsQL = 11–30 EA per 5 days (varies by pack: examples shown include 11 EA/5 days and 30 EA/5 days)
    TierListed at tier 5 in formulary rows with QL per therapy course specified.
    ImplicationQuantity limits are per therapy pack/course — verify pack type when adjudicating claims.
    Antiretroviral single-tablet regimens — QL 30 EA per 30 days
    Antiretroviral single‑tablet regimensCommon QL = 30 EA per 30 days for many STRs (e.g., emtricitabine‑tenofovir entries)
    ExamplesGENVOYA, TRIUMEQ, other ARV single‑tablet regimens show 30 EA per 30 days in listings.
    Provider noteAdhere to monthly QL for ARV chronic therapy; check formulation/strength for exceptions.
    abiraterone acetate 250 mg — QL 120
    abiraterone acetate 250 mgPA; QL = 120 EA per 30 days
    UsageListed with PA and quantity limit in the antineoplastic agents section.
    Provider actionPA required and QL enforced for dispensing; include justification in PA submission.
    abiraterone acetate 500 mg — QL 60
    abiraterone acetate 500 mgPA; QL = 60 EA per 30 days
    Formulary noteHigher strength has lower monthly QL compared with 250 mg strength as listed.
    ActionEnsure PA and quantity justification accompany requests for monthly supplies beyond the QL.
    ALECENSA oral capsule — QL 240
    ALECENSA (alectinib) oral capsulePA; QL = 240 EA per 30 days
    TierListed at tier 5 with PA and QL in formulary lines.
    Provider notePA required for coverage; QL indicates monthly maximum dispensed.
    ALUNBRIG oral tablet — QL 30
    ALUNBRIG (brigatinib) oral tabletPA; QL = 30 EA per 30 days
    Formulary tierListed at tier 5 with PA and QL annotations.
    ImplicationDispensing beyond QL requires PA/exception per plan rules.
    BRUKINSA oral tablet — QL 60
    BRUKINSA oral tabletPA; QL = 60 EA per 30 days
    TierListed at tier 5 with PA and QL in formulary lines.
    Provider actionInclude QL consideration when submitting PA/claim.
    everolimus (oral tablet) — QL 30
    everolimus (oral tablet)PA; QL = 30 EA per 30 days
    Formulary placementListed with PA and QL in the antineoplastic agents section.
    Provider notePA required for certain strengths; adhere to monthly QL.
    LENVIMA therapy packs — QL varies (30/60/90 per 30 days)
    LENVIMA therapy packsQL varies by dose — examples shown: 30, 60, 90 EA per 30 days depending on pack/dose
    Formulary noteListed with PA and QL where applicable; exact QL depends on specific therapy pack.
    Provider actionVerify pack/dose to determine applicable monthly QL when adjudicating claims.
    REVLIMID oral capsule — QL 30
    REVLIMID oral capsulePA; QL = 30 EA per 30 days
    Formulary statusListed at tier 5 with PA and monthly QL.
    Provider implicationPA required for coverage and QL enforced per month.
    PIQRAY — QL 30 EA per 30 days; packs 56 EA per 28 days
    PIQRAY (various strengths)PA; QL = 30 EA per 30 days; some therapy packs show QL = 56 EA per 28 days
    Formulary noteValues differ by strength/formulation and pack type (monthly or 28‑day pack).
    Provider actionConfirm pack type/strength to apply the correct QL when processing claims.
    ROZLYTREK — QL 180 EA/30 days or 360 EA/30 days (packet)
    ROZLYTREK oral capsule/packetPA; QL = 180 EA per 30 days (capsule) or QL = 360 EA per 30 days (packet)
    Formulary noteDifferent QLs for capsule versus packet formulations as listed.
    Provider implicationUse the line‑specific QL when authorizing or adjudicating claims.
    RYDAPT oral capsule — QL 224 EA per 28 days
    RYDAPT oral capsulePA; QL = 224 EA per 28 days
    Formulary noteListed with PA and a 28‑day quantity limit in the formulary lines.
    Provider actionPA required and QL enforced — include justification for quantities beyond limit.
    VENCLEXTA starting pack — QL 84 EA per 365 days
    VENCLEXTA starting packPA; QL = 84 EA per 365 days
    Formulary noteStarting pack has an annual QL indicated in the formulary.
    Provider actionPA required for coverage of the starting pack; monitor annual QL usage.
    XPOVIO therapy packs — QL commonly 8 EA per 28 days
    XPOVIO therapy packsPA; QL commonly = 8 EA per 28 days; some packs show QL = 24 EA per 28 days
    Formulary noteQuantity limit varies by therapy pack schedule and strength.
    Provider actionConfirm specific pack to apply appropriate QL when authorizing or adjudicating.
    MRESVIA vaccine — QL 0.5 ML per 999 days
    MRESVIA vaccineQL = 0.5 ML per 999 days
    Formulary noteVaccine listed with an extended interval quantity limit in the formulary.
    Provider implicationVery infrequent dosing — QL reflects long dosing interval for this product.
    varenicline tartrate — QL 504 EA per 365 days
    varenicline tartrateQL = 504 EA per 365 days (multiple entries: starter and tablet listings)
    Tier/statusListed with QL in smoking cessation agents section.
    Provider noteAnnual QL applies across listed varenicline formulations as noted.
    fluticasone-salmeterol — QL 60 EA per 30 days
    fluticasone‑salmeterol (powder inhalation)QL = 60 EA per 30 days
    Formulary placementListed with QL in respiratory/inhaled agents section.
    Provider actionAdhere to monthly QL or submit PA/exception if clinically required.
    PROLASTIN-C (IV solution) — QL noted (unspecified)
    PROLASTIN-C (IV solution)QL noted in formulary (specific value not included in excerpt)
    PlacementListed under Blood Derivatives / PROLASTIN‑C lines with QL annotation.
    ActionRefer to full formulary table for the exact QL value when processing claims.
    XARELTO oral suspension reconstituted — QL 600 ML per 30 days
    XARELTO oral suspension (reconstituted)QL = 600 ML per 30 days
    Formulary noteListed with QL in antithrombotic/anticoagulant section.
    Provider implicationAdjudicate per milliliter QL for suspension formulations.
    PROAIR RESPICLICK — QL 2 EA per 30 days
    PROAIR RESPICLICKQL = 2 EA per 30 days
    Formulary placementListed in respiratory products with a small per‑month QL.
    Provider actionApply QL per 30‑day period when adjudicating inhaler claims.
    NEULASTA, UDENYCA, other injectables — QL 2.4 ML per 28 days
    NEULASTA / UDENYCA and similar injectablesQL examples = 2.4 mL per 28 days (injectable biologic volume limits)
    Formulary noteSome biosimilars and pegfilgrastim products list QL by mL over 28 days.
    Provider implicationAdjudicate injectable claims using the specified mL QL and PA where indicated.
    PROMACTA tablets — assorted QLs by strength
    PROMACTA tablets (by strength)QLs = 360 EA/30 days (12.5 mg), 180 EA/30 days (25 mg), 90 EA/30 days (50 mg), 60 EA/30 days (75 mg)
    Formulary placementListed under hematopoietic agents with PA and specific QLs per strength.
    Provider actionInclude strength‑specific QL when submitting PA or claims for PROMACTA.
    Multiple hematopoietic agents — common QL 102 EA per 365 days
    Hematopoietic agents common QLQL = 102 EA per 365 days appears consistently for many hematologic agents (e.g., ARANESP, PROCRIT, NEULASTA biosimilars lines)
    ApplicationAnnual QL applied to multiple injectables/hematologic product lines as listed.
    Provider noteRefer to each product line for PA and any per‑period volume/EA specifics.
    Statin class QLs — various QLs shown
    Statin class examplesQL examples shown for statins (e.g., rosuvastatin QL = 30 EA per 30 days; simvastatin QL = 45 EA per 30 days for some strengths)
    Formulary noteQL values vary by product and strength within the statin class.
    Provider actionApply the product‑specific monthly QL when adjudicating lipid‑lowering therapy claims.

    Policy Revision History

    2026-01-20formulary_updateLatest

    AmeriHealth Medicare PPO formulary updated (document current as of 1/20/2026) with comprehensive Drug List including tiering, PA, QL, and ST annotations.

    2025-01-01annual_update

    Standard annual formulary update cycle (most major changes typically occur January 1); members are advised to review changes for the new benefit year.

    2026-?monthly_postings

    Formulary changes may be posted monthly online; the plan posts updates to amerihealthmedicare.com/formulary.